Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if the study drug, FMX-103, is safe to give and if it
helps people with moderate-to-severe papulopustular rosacea.
The investigational product is FMX-103 minocycline foam. Two concentrations of the
investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be
applied once daily to the face for the 12-week treatment duration of the study.
Approximately 210 patients will participate in this study.